Download to read offline
BALS167
- 1. visit our website: www.flemingeurope.com OURSPEAKER PANELOur features 2015 AT A GLANCE Thought-provoking agenda Valuable insight from 15+ experts representing top pharma and biotech companies Inspiring case studies Interactive group sessions Building an action plan activities Project & Portfolio Management in the Pharmaceutical Industry 28 – 29 October 2015, Vienna, Austria 11th • Program & lifecycle management • Project Prioritisation tools • Initiatives to improve Project Delivery Capabilities • Handling complex projects • Portfolio optimisation • Resource management • Crossing cultural barriers: unknown unknowns • R&D productivity measures • PPM in licensing strategies • Co-development programs and partnerships and more... Media Partners: Ulrike Grimm, Vifor Pharma Vice President Head Global Project and R&D Alliance Management Hannes Loferer, Onconova Europe VP Project Planning & Portfolio Management Jörg Meil, Boehringer-Ingelheim Animal Health Head Global Pharmaceuticals R&D and International Project Management Peter Luke, Novo Nordisk Director of Global Project Office Rainer Mussmann, Novartis Associate Director, Project Management Office Yvette Miata Petersen, Novartis Associate Director, Project Management Office Sakir Mutevelic, Baxter BioScience Director Global Program & Portfolio Management Frank Rebers, Genmab Associate Director Project Management Office Verena Lutz, Roche Global Project Manager, Portfolio & Strategy Marie Bernasconi Pierre Fabre Pharmaceuticals Head of R&D Portfolio and Program Strategy Chiara Mazzoli, Chiesi Project Manager Katrine Husum, LEO PHarma Senior Project Leader Jacques Marcel, Sanofi Pasteur - TBC Head of Project Management Office, Commercial Operations
- 2. OUR ADVISORY COMMITTEE ‘Veryeducational and pleasant three days. The workshop was great, as well as the interactions and discussions. Nicely organised!’ Project Manager, LEK Pharmaceuticals “Good to see that small and big, traditional and innovative industries face the same challenges with the same tools” Head of Project Management and Processes, Chiesi Farmaceutici “Excellent event, thanks!” Global Project Manager, Zentiva “Your event was a great opportunity to network and share experience. It was on a very good expert level.” Director Competitive R&D Intelligence Boehringer Ingelheim “Very good speakers with bright ideas. The event was very enlightening and provided a great opportunity to meet the Best in the industry.” Head of International Business Development Acino Pharma 11th Project & Portfolio Management in the Pharmaceutical Industry CxOs, SVPs, VPs, Global heads, Heads, Directors, Senior Managers, Managers, Team Leaders, Researchers, Scientists of Pharma/ Biotech companies responsible for: Portfolio Management, Project Management, Lifecycle Management, Pharmaceutical Development, R&D, Portfolio Strategy, Strategic Planning & Decision, Strategy & Portfolio Analysis, Portfolio Selection, Decision Analysis, Business Development, Alliances... A large number of companies have registered for our PPM events, is your company among them? Whay do they say about it Abbott, Acino Pharma, Actelion, AHP Manufacturing - Wyeth Medica Ireland, Algeta, ALK-Abello, Almirall, Amgen, Apogenix, Arterium Pharmaceutical Corporation, Astellas Pharma Europe, AstraZeneca,AxelliaPharmaceuticals,BaxterInternational,Bayer Healthcare, Bayer Schering Pharma AG, Boehringer Ingelheim, Catenion, Celgene, CEVA Sante Animale, Chiesi Farmaceutici, CSL Behring, DebioPharm, Dompe Pha.R.Ma, Elli Lilly, Enrich Consulting, F.Hoffmann-La Roche, Ferring International Center, Fertin Pharma, Fresenius Medical Care, Galapagos, Galderma, Genentech, Genmab, Genzyme, GlaxoSmithKline, Glenmark Pharmaceuticals, Grunenthal GmbH, Hovione FarmaCiencia, IMS Health, Institute de Recherche Pierre Fabre, Ipsen, Kinapse, LEO Pharma, Lundbeck, Medimmune, Merck KGaA, Merck Serono, Merck Sharp & Dohme, Merial, Merz Pharmaceuticals GmbH, Novartis, Novo Nordisk, Nycomed, Orion Pharma, Pfizer, Pharmaxis, Ratiopharm, Roche, Sandoz, Sanofi, Sanofi Pasteur, Santen, Sartorius AG, Sigma-Tau Spa, Solvay Pharmaceuticals, Stada, Swedish Orphan Biovitrum, Teva Pharmaceuticals, UCB, Vertex Pharmaceuticals, Vifor Pharma, Wockhardt, Xellia Pharmaceuticals, Zambon Spa... Who will you meet Jörg Meil Boehringer-Ingelheim Animal Health Head Global Pharmaceuticals R&D and International Project Management Hannes Loferer Onconova Europe GmbH VP Project Planning and Portfolio Management Varada Bapat Wockhardt Associate Vice President Project Management
- 3. CONFERENCE FEATURES 11th Project &Portfolio Management in the Pharmaceutical Industry Meet & Greet Networking Session To boost networking and interactivity right from the beginning, we will start the conference with a small exercise. The attendees will have 10 minutes to exchange as many business cards as possible. Building An Action Plan Participants will be asked to “Build An Action Plan”, a step by step guide, throughout the two days of the conference. This session is an essential part of the whole conference programme that has been designed to give you take-aways to act upon, therefore we encourage participants to engage in conversations, exchange observations and share knowledge and experience. • After each group of presentations, participants will be given the time to further discuss in groups concerns in that particular area and solutions that could enhance their roles as project and portfolio managers and that could be implemented in their organisations. • There will be four group activities where the discussion should be focused on creating a step by step plan that could be used by participants back in their offices. • Each group leader will present to the whole audience their group solution with a step by step action plan. Breakout Sessions Breakout sessions are interactive, guided discussions hosted by a facilitator to discuss some of the key issues presented earlier in the day’s sessions. Participants will join a table of interest and become an active part of the discussion at hand. To get the most out of this interactive session and format please come prepared to share examples from your work, share some ideas with your peers, be a part of group discussions, and, most importantly, participate in active idea sharing. The Talk After an introduction to the topic given by one of our speakers, participants will have the opportunity to share their knowledge and experience. We will have 5 chairs arranged in an inner circle and will start with a ‘closed circle‘ with speakers. The audience outside the circle will listen to beginning of the discussion and when a member of the circles leaves and a chair is left empty, any member of the audience can, at any time, occupy the empty chair and join the circle and the discussion. The discussion continues allowing several people to participate in the conversation. Spotlight Session Our interactive spotlight session address the differences and similarities in project and portfolio management in specific therapeutic areas. Panellists share their own thoughts and experience and react to the audience’s questions. Networking Cocktail Reception Our cocktail party will take place after the first day of the conference and it is aimed to promote networking between participants and can be an opportune time for helping your career.
- 4. 28 October 2015 8:30 Registrationcoffee 9:00 Welcoming note from Fleming Europe 9:05 Opening remarks from the Chair 9:15 “Meet & Greet Networking Session” 9:20 Translating Companies Strategies into Projects • Does your company have a strategy and do people know and understand it? • Does project portfolio strategy have a direct link to the organisation strategy? • How to take a holistic approach Ulrike Grimm, Vifor Pharma Vice President Head Global Project and R&D Alliance Management 10:00 Handling Complex Projects/Programs in Complex Matrix Organisational Structure • Main focus on Project Team and Project Sub-teams Structure • Reflecting on experience in developing competence framework for Project/Program Management success across the organisation Sakir Mutevelic, Baxter BioScience Director Global Program & Portfolio Management 10:30 Project Prioritization - Getting Project Decisions Right to Achieve Success • What are the priorities in a changing environment with limited resources? • How do we ensure our project portfolio best supports the company strategy? • Selecting the best set of projects to achieve the organisation‘s goals • Determining what portfolio-level metrics could be used to characterise what the executive team would see as a ‚good‘ portfolio Jörg Meil, Boehringer-Ingelheim Animal Health Head Global Pharmaceuticals R&D and International Project Management 11:00 Morning coffee & networking 11:30 Project Optimization –The Path from Discovery to Early Development • How can the definition of Key Scientific Questions drive optimized Project development • Risk Management Plans: A useful tool in optimization • Implementation of “Optimized” decisions: Team or Management Responsibility?Dealing with emotional reactions to optimization Yvette Miata Petersen, Novartis Associate Director, Project Management Office 12:00 How to Ensure that the Necessary Resources Are Available • How to best align the delivery of projects considering the constraints of internal resources and overall R&D budget • Re-thinking the deployment of resources internally in light of the rising numbers of projects across the industry at every development phase • Establishing an integrated R&D operations environment to align project, resource, finance and portfolio management 12:30 GROUP ACTIVITY – Building an Action Plan Step 1 • How do you organise roles and responsibilities to optimise performance? • How do you overcome cross-cultural barriers? • How to break-up silos in an organisation • What criteria should be used when prioritising projects? When terminating a project? What are the procedures / strategies to best allocate those resources to a new project? Are they aligned with company‘s strategy? 12:50 Lunch 14:00 Aligning Portfolio with the Organisation’s Goals and Objectives – From Past to Future. • Portfolio analysis and tracking • Setting goals and creating pipeline strategy • Long term forecasting of resources and budgets Frank Rebers, Genmab Associate Director Project Management Office 14:30 Delivering Portfolio Optimisation • Predictive modelling and simulation & optimisation capabilities • Data sources and criteria selection of new pipeline candidates • Uncertainties of the elements - Communicating uncertainty in your portfolio 15:00 Building a Portfolio for the Future – Looking into Market Access and Reimbursement • Incorporating pharma-economics in early stages of product development to understand the reimbursement landscape • How can payers influence R&D choices? • How can pharmaceutical companies launch new products and satisfy payers with different standards and needs? • How does the increased Payer focus match with being Patient Centric? Katrine Husum, LEO PHarma Senior Project Leader 15:30 Afternoon tea & networking 16:00 BREAKOUT SESSIONS Sharing, Hedging and Mitigating Risk • Risk valuation as a powerful tool in project and portfolio management • How do risk assessment results drive portfolio decision? Dynamic Project and Portfolio Management What is the role of regulatory affairs and HTAs in defining key project parameters in drug development? Which challenges do the EMA and national HTAs and their different requirements represent? And how can this be managed from today‘s perspective? Does this impact the valuation of drug development projects (e.g. also in the context of licensing negotiations? Big Data – How can the portfolio benefit from big data? • Can Big Data analytics enable faster and better decision making in R&D from new insights, leading to improved R&D productivity? 16:30 GROUP ACTIVITY – Building an Action Plan Step 2 • What are the methods to identify new pipeline candidates? • How can you best monitor that the portfolio is at all times aligned with your company‘s goals? • How does the performance of project portfolios relies on uncertainties? • How should expectations about portfolio performance be reviewed according to those uncertainties? • How can you best apply the payers‘ concern to your portfolio selection? 16:50 The Talk – The Project & Portfolio Management Function • Is Project & Portfolio Management a discipline on its own? • Is It a Marketing function? Or a Commercial one? should PPM be integrated in R&D? Can it be an independent function? • What are the pros and cons of each of these options? • What would be the ideal reporting system? Marie Bernasconi, Pierre Fabre Pharmaceuticals Head of R&D Portfolio and Program Strategy 17:20 Closing remarks from the Chair Speakers and delegates are cordially invited to attend a Networking Cocktail Reception MAIN FORUM DAY tel.: + 421 257 272 290, fax: + 421 255 644 490 killian.mabena@flemingeurope.com, www.flemingeurope.com
- 5. 29 October 2015 MAINFORUM DAY 9:00 Welcoming note from the Chair 9:10 SPOTLIGHT SESSION: Project & Portfolio Management in Specific Therapeutic Areas Each of the panel speakers will deliver a 15-minute presentation, a case study on the different project and portfolio management strategies and approaches used for specific therapeutic areas (oncology, diabetes, orphan drugs, neurology, immunology, etc.) The presentations will be followed by a discussion with the panel moderator and the audience. Managing an Early clinical Portfolio in the Autoimmunity and Immunology area Rainer Mussmann, Novartis Associate Director, Project Management Office Pathways for of new oncology drugs – with emphasis on early approval pathways (USA vs Europe) • Two case studies from a project management perspective • Biologic with immune based mechanism in lung cancer • Small molecule signal pathway inhibitor in hematological cancer • Retrospective summary of key decisions on the development path, their risks and impact. • Lessons learned summary. Hannes Loferer, Onconova Europe VP Project Planning & Portfolio Management 10:30 Quantity Measures for R&D Performance • Capacity Planning and Performance Tracking – how to integrate progressive KPIs systems to evaluate projects • How to leverage resource planning and pipeline operations to deliver on strategic R&D goals • How to monitor the expenses in R&D and control the project end to end 11:00 Morning coffee & networking 11:30 Integrating Tools in R&D Portfolio Management • How tools ensure the most strategic value out of companies R&D investment • Connecting and harmonising functional areas within the organisation • Real-time data available across the organisation to support decision making 12:00 GROUP ACTIVITY: Building an Action Plan Step 3 • What methods and techniques do you use to measure R&D productivity? • What are the do‘s and don‘ts? • What tools do you use to support R&D performance? 12:20 Lunch 13:20 Collaborative Project Management: Empowering Project Team Members and Overcoming Barriers of Time and Space • What are the benefits of collaborative project management? • How can collaborative project management improve efficiencies, enhance competitive advantage, and result in more successful projects? Verena Lutz, Roche Global Project Manager, Portfolio & Strategy 13:50 Project Team Members: Collaboration and Communication • Team members: Role and accountabilities • Why should team members be empowered? • What tools can the project manager use to increase collaboration and communication within the team? • New challenges: multicultural and virtual teams • What is a virtual team? How to manage the obstacles of virtual teams? Chiara Mazzoli, Chiesi Project Manager 14:20 Developing New Models of Partnership: Innovation through Internal and External Collaboration • Identifying the drivers, benefits and advantages of partnerships • How does the partnership affect the portfolio? • Translational research support • Designing the right global portfolio of R&D partners and service providers and avoid complexity and inefficiency • How to set up and effectively utilise a network of partner service providers to dramatically improve R&D performance 14:50 GROUP ACTIVITY: Building an Action Plan Step 4 • What are the most efficient internal and external collaboration models? • How do you manage the complexity of collaboration with academia and solution providers? • What are the challenges? How do you overcome those? 15:10 WRAP UP Session Attendees will have the opportunity to share their findings and take-aways after two days of interesting and valuable presentations and will be given the opportunity to ask extra questions to speakers. 15:20 Closing remarks from the Chair 15:30 Farewell Coffee and Networking tel.: + 421 257 272 290, fax: + 421 255 644 490 killian.mabena@flemingeurope.com, www.flemingeurope.com
- 6. 11th Annual Project &Portfolio Management in the Pharmaceutical Industry 28 – 29 October 2015, Vienna, Austria Terms and Conditions: These terms and conditions represent an integral part of this contract between Event Production, s.r.o. and a client, which is specified above, and who by signing this registration form fully and without any doubt or uncertainty accepts all following terms and conditions: 1. Payment terms. Event Production, s.r.o. (hereinafter as “EP”) requires the full payment of the invoiced amount within 5 working days from the issue date of the invoice. EP reserves the right to refuse entry to any client who does not pay the invoice in full and on time. The registration fee includes: conference documentation, admission to all conference sessions, lunches and refreshments, admission to networking social breaks during the event. The registration fee does not include: travel, hotel accommodation, transfers or insurance. 2. Hotel accommodation. Overnight accommodation is not included in the registration fee. A reduced rate may be available for EP’s clients at the hotel hosting the event. The reservation form will be sent to the client after the venue has been confirmed, but no later than one month before the event begins. 3. Cancellation by client. The client has the right to cancel his/her participation in the event. Cancellation must be received by EP in writing, either by mail, email or fax. If the client cancels with more than one month’s advance notice before the start of the event, EP shall be entitled to retain and charge 50% of the total invoiced amount. If the client cancels with one month’s (or less) advance notice, or fails to attend the event, then the client shall not be entitled to any refund nor any discount. Client’s failure to attend the event does not cancel, decrease or in any matter waives the client’s obligation to fully pay the fee invoiced to the client by EP. 4. Cancellation by EP. While every reasonable effort is made to adhere to the advertised program, circumstances out of the control of EP can arise, which may cause changes in the program, including but not limited to changes in the content, date(s), location or venue, or special features of the planned event. Such circumstances include but are not limited to acts of terrorism, war, extreme weather conditions, compliance with government requests, orders and legal requirements, failure of third party suppliers to timely deliver, and failure to register the minimum targeted amount of attendees for a given event. EP reserves the right to change the content, date(s), location or venue and/or special features of an event, to merge the event with another event, or to postpone it or cancel it entirely as appropriate under the circumstances. Client agrees that EP shall not be liable for any cost, damage or expense which may be incurred by client as a consequence of the event being changed, merged with another event, postponed or cancelled and client agrees to hold EP harmless and to indemnify EP for any liability caused by any such changes, mergers, postponements or cancellations to the Client. 5. Cancellation of the event. In case EP cancels the event, EP may offer the client a full credit up to the amount actually paid by the client to EP. This credit shall be valid for up to one year from the issue date of the invoice to attend any of EP’s events. The client shall not be entitled to this credit as a contractual right. 6. Clients identification information. By signing of this sales contract and these terms and conditions the client gives full right to EP to share the client’s identification information such as, but not limited to, client’s name, address, email addresses, phone numbers and names of representatives with third parties, which participated on the same event as the client. 7. Governing law. This contract shall be governed and construed in accordance with the laws of the Slovak Republic (not including its conflict of laws provisions). Any disputes arising out of this contract shall be brought before the courts of the Slovak Republic situated in the city of Bratislava in the Slovak Republic. 8. Other currencies. In case that client requests payment in other than EP’s official currency (EUR), EP reserves the right to apply 8% currency risk surcharge to the actual exchange rate. Sales Contract Please complete this form and send it back to: E-mail to: killian.mabena@flemingeurope.com or FAX: + 421 255 644 490 Client Identification Details (Please complete form IN CAPITAL LETTERS for each client) Ms Mrs Mr Surname: Name: Job Title: Email: Ms Mrs Mr Surname: Name: Job Title: Email: Ms Mrs Mr Surname: Name: Job Title: Email: Company/organisation Details Name: VAT Number: (VAT No. for EU members / Tax Number for non-EU members) Contact person: Email: Address: City: Country: Phone: Under European Union and Austrian tax regulations delegates are required to pay VAT in any conference taking place in the Austria. Delegates may be entitled to reclaim this cost. Payment Method Please debit my Visa Eurocard/Mastercard Diners club Card Billing Address: Street: City: Post/Zip Code Card Holder´s Name: Card Holder´s Signature: Card Number: Visa CVC Number or Eurocard/Mastercard CVV Number (last 3 digits on the back of the card) Valid from Expiry Date I agree to Event Production s.r.o. debiting my card. Authorization and Acceptance of Sales contract Terms Conditions I hereby declare I am authorised to sign this contract and terms conditions in the name of the company/organisation: Name: Date: Signature: Booking is invalid without a signature Conference Code: BALS167 Mlynské Nivy 71, 821 05 Bratislava, Slovakia IČO: 44 59 74 52, IČ DPH: SK2022754448 1 Agreed Price of the service 18 € administration charge and 20% Austrian VAT will be applied Payment is required within 5 working days If you wish to pay in USD ($) or GBP (£) please contact us for more details. In the name of Event Production s.r.o. I hereby declare Event Production s.r.o. will adhere to this sales contract terms conditions Eduard Vacula, Director € 1595Industry Professional